CN1304401A - calcilytic化合物 - Google Patents

calcilytic化合物 Download PDF

Info

Publication number
CN1304401A
CN1304401A CN99807083A CN99807083A CN1304401A CN 1304401 A CN1304401 A CN 1304401A CN 99807083 A CN99807083 A CN 99807083A CN 99807083 A CN99807083 A CN 99807083A CN 1304401 A CN1304401 A CN 1304401A
Authority
CN
China
Prior art keywords
group
dimethyl
naphthyl
hydroxyl
ethamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN99807083A
Other languages
English (en)
Chinese (zh)
Inventor
P·K·巴特纳加
J·L·布尔格斯
J·F·卡拉汉
R·R·卡尔沃
E·G·德尔马
M·A·拉戈
T·T·恩古云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp, NPS Pharmaceuticals Inc filed Critical SmithKline Beecham Corp
Publication of CN1304401A publication Critical patent/CN1304401A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/33—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN99807083A 1998-04-08 1999-04-08 calcilytic化合物 Pending CN1304401A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8109398P 1998-04-08 1998-04-08
US60/081,093 1998-04-08

Publications (1)

Publication Number Publication Date
CN1304401A true CN1304401A (zh) 2001-07-18

Family

ID=22162059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99807083A Pending CN1304401A (zh) 1998-04-08 1999-04-08 calcilytic化合物

Country Status (33)

Country Link
US (1) US6395919B1 (enExample)
EP (1) EP1070048B1 (enExample)
JP (1) JP2002510671A (enExample)
KR (1) KR20010042526A (enExample)
CN (1) CN1304401A (enExample)
AP (1) AP1271A (enExample)
AR (1) AR018177A1 (enExample)
AT (1) ATE303358T1 (enExample)
AU (1) AU752389B2 (enExample)
BG (1) BG104916A (enExample)
BR (1) BR9909486A (enExample)
CA (1) CA2327279A1 (enExample)
CO (1) CO5031246A1 (enExample)
DE (1) DE69927008T2 (enExample)
DZ (1) DZ2751A1 (enExample)
EA (1) EA200001039A1 (enExample)
EG (1) EG24178A (enExample)
ES (1) ES2247795T3 (enExample)
HU (1) HUP0101346A3 (enExample)
ID (1) ID27004A (enExample)
IL (1) IL138918A0 (enExample)
MX (1) MXPA00009844A (enExample)
MY (1) MY121054A (enExample)
NO (1) NO20005006L (enExample)
NZ (1) NZ507288A (enExample)
OA (1) OA11499A (enExample)
PE (1) PE20000415A1 (enExample)
PL (1) PL343357A1 (enExample)
SK (1) SK14852000A3 (enExample)
TR (1) TR200002896T2 (enExample)
UA (1) UA58586C2 (enExample)
WO (1) WO1999051569A1 (enExample)
ZA (1) ZA200005369B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180628A1 (es) * 1999-07-31 2002-07-30 Smithkline Beecham Corp Compuestos calcioliticos
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) * 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
AU2001277752A1 (en) 2000-08-11 2002-02-25 Japan Tobacco Inc. Calcium receptor antagonists
ATE343390T1 (de) * 2000-10-25 2006-11-15 Smithkline Beecham Corp Kalzilytische verbindungen
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US7105537B2 (en) 2003-01-28 2006-09-12 Bristol-Myers Squibb Company 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
ZA200505587B (en) 2003-04-23 2006-09-27 Japan Tobacco Inc Casr antagonist
JPWO2004106280A1 (ja) 2003-05-28 2006-07-20 日本たばこ産業株式会社 ＣａＳＲアンタゴニスト
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
JP2007522148A (ja) * 2004-02-06 2007-08-09 スミスクライン・ビーチャム・コーポレイション カルシウム受容体アンタゴニスト化合物
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
ES2400693T3 (es) * 2005-09-02 2013-04-11 Amgen Inc. Regulación del equilibrio de fluido intestinal usando calcimiméticos
CA2681582C (en) * 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
JP5628687B2 (ja) * 2008-12-24 2014-11-19 第一三共株式会社 インダニル化合物
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
DE3301198A1 (de) 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ES2158996T3 (es) * 1995-09-21 2001-09-16 Lilly Co Eli Agonistas beta3 adrenergicos selectivos.
WO1997037967A1 (en) 1996-04-09 1997-10-16 Nps Pharmaceuticals, Inc. Calcilytic compounds

Also Published As

Publication number Publication date
CO5031246A1 (es) 2001-04-27
NZ507288A (en) 2003-05-30
ES2247795T3 (es) 2006-03-01
PL343357A1 (en) 2001-08-13
ZA200005369B (en) 2001-12-18
BR9909486A (pt) 2001-11-06
JP2002510671A (ja) 2002-04-09
AU3481999A (en) 1999-10-25
AU752389B2 (en) 2002-09-19
EP1070048B1 (en) 2005-08-31
IL138918A0 (en) 2001-11-25
AP1271A (en) 2004-04-21
NO20005006D0 (no) 2000-10-04
SK14852000A3 (sk) 2001-05-10
NO20005006L (no) 2000-10-04
DE69927008D1 (de) 2005-10-06
DZ2751A1 (fr) 2003-09-15
WO1999051569A1 (en) 1999-10-14
AR018177A1 (es) 2001-10-31
MXPA00009844A (es) 2003-07-14
PE20000415A1 (es) 2000-05-21
EG24178A (en) 2008-09-28
ATE303358T1 (de) 2005-09-15
OA11499A (en) 2004-05-05
TR200002896T2 (tr) 2001-01-22
HK1034243A1 (en) 2001-10-19
HUP0101346A3 (en) 2003-03-28
DE69927008T2 (de) 2006-03-16
ID27004A (id) 2001-02-22
EP1070048A1 (en) 2001-01-24
KR20010042526A (ko) 2001-05-25
CA2327279A1 (en) 1999-10-14
AP2000001931A0 (en) 2000-09-30
EA200001039A1 (ru) 2001-04-23
BG104916A (en) 2001-06-29
MY121054A (en) 2005-12-30
US6395919B1 (en) 2002-05-28
EP1070048A4 (en) 2001-11-07
HUP0101346A2 (hu) 2001-08-28
UA58586C2 (uk) 2003-08-15

Similar Documents

Publication Publication Date Title
CN1304401A (zh) calcilytic化合物
CN1280288C (zh) 作为1型纤溶酶原激活物抑制剂(pai－1)的抑制剂的取代萘基吲哚衍生物
CN1032203C (zh) 制备取代2-吡啶酮和吡啶-2-硫酮的方法
CN1168709C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸的α-羟基、-氨基和卤代衍生物
CN1149214C (zh) 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
CN1259120A (zh) 钙阻滞类化合物
CN1280575A (zh) 新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
CN87100040A (zh) 二芳基烷基取代的烷基胺、其制备工艺方法、应用以及含有该类化合物的药物
CN1542002A (zh) 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
CN1444570A (zh) 非甾体抗炎药
CN1174196A (zh) 稠杂环吡啶
CN1312800A (zh) 治疗用的联芳基衍生物
CN1088581A (zh) 内皮素受体拮抗剂
CN1309655A (zh) 可用于治疗脂血异常、动脉粥样硬化和糖尿病的环状化合物、药物组合物和制备方法
CN1774244A (zh) 用于治疗代谢紊乱的化合物
CN1112364A (zh) 哌嗪衍生物及其盐
CN1362951A (zh) 二杂－取代的金属蛋白酶抑制剂
CN1074904A (zh) 苯并呋喃基-和噻吩基甲硫基-链烷羧酸衍生物
CN1061414A (zh) 单环β-内酰胺类抗生素的杂芳酰基衍生物
CN1993344A (zh) 可用作香草素拮抗剂的色酮衍生物
CN1202084C (zh) 苯稠合杂环衍生物及其用途
CN1046123C (zh) 烷氧亚氨基乙酰胺类化合物的生产方法
CN1511034A (zh) 用于治疗与过度细胞因子活性相关的疾病的异噁唑酮化合物
CN1849306A (zh) 基质金属蛋白酶抑制剂
CN1283196A (zh) N－苯基酰胺和n－吡啶基酰胺、其制备方法和含有它们的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication